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Pterygium and genetic polymorphisms of the DNA repair enzymes
XRCC1, XPA, and XPD
Purpose: Pterygium is an ultraviolet (UV) related disease. UV radiation can produce DNA damage, which is repaired by
the DNA repair systems. Among the DNA repair systems, the base excision repair (BER) and nucleotide excision repair
(NER) systems are the major ones involved in repairing UV-induced DNA damage; X-ray repair cross complementary 1
(XRCC1) and human 8-oxoguanine DNA glycosylase 1 (hOGG1) are two BER genes, and xeroderma pigmentosum group
A (XPA) and xeroderma pigmentosum group D (XPD) are two NER genes. Polymorphisms of these genes are associated
with the differences in their repair DNA damage capacity, and they modulate the susceptibility to cancer. Because the
polymorphism of hOGG1 was reported to be associated with pterygium, it is logical to assume the correlation between
XRCC1, XPA, and XPD polymorphisms and pterygium formation.
Methods: One hundred and twenty-seven pterygium patients and 103 volunteers without pterygium were enrolled in this
study. Polymerase chain reaction based analysis was used to resolve the XRCC1 codon 107, 194, 280, and 399; XPA A23G;
XPA codon 228; and XPD codon 751 polymorphisms.
Results: There were significant differences in the frequency of genotypes and alleles of XRCC1 codon 194 and 399
polymorphisms between the groups. In codon 194, individuals who carried at least 1 Trp allele had a decreased risk of
developing pterygium compared to those who carried the Arg/Arg wild-type genotype (odds ratio [OR]=0.58; 95% CI:
0.34–0.98). In codon 399, individuals who carried at least 1 Gln allele had a threefold increased risk of developing
pterygium compared to those who carried the Arg/Arg wild-type genotype (OR=3.06; 95% CI: 1.78–5.26). There were
no significant differences in the frequency of the genotypes and alleles of XRCC1 codon 107 and 280, XPA A23G, and XPD
codon 751 polymorphisms between the groups. The XPA codon 228 polymorphism was not detected in any of the cases
or controls.
Conclusion: The XRCC1 codon 194 polymorphism causes a decreased risk of developing pterygium, but the codon 399
polymorphism increases the risk. There is no correlation between pterygium and XRCC1 codon 107 and 280, XPA A23G,
and XPD codon 751 polymorphisms.
Although  the  pathogenesis  of  pterygia  is  still  under
investigation,  epidemiological  evidence  suggests  that
ultraviolet  (UV)  irradiation  plays  the  most  important  role
[1-3].  Moreover,  after  abnormal  levels  of  the  tumor
suppression protein, p53 protein and p53 gene mutation were
found in the epithelium, an increasing number of researchers
felt  that  pterygium  is  a  UV-related,  uncontrolled  cell
proliferation consistent with that of a tumor [4-8].
UV irradiation can produce DNA damage, which will
lead  to  gene  mutation  and  uncontrolled  cell  proliferation
[9-11]. Most DNA damage is repaired by the DNA repair
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system. In humans, more than 70 genes are involved in five
major  DNA  repair  pathways:  direct  repair,  base  excision
repair (BER), nucleotide excision repair (NER), mismatch
repair, and double strand break repair [12,13]. The NER and
BER  systems  are  the  major  repair  systems  involved  in
repairing UV-related DNA damage [11].
X-ray repair cross complementary 1 (XRCC1) is a major
gene in the BER system, and xeroderma pigmentosum group
A (XPA) and xeroderma pigmentosum group D (XPD) are two
important genes in NER system [11,14,15]. Polymorphisms
of the genes have an effect on the host’s capacity to remove
DNA damage and are reported to modulate the susceptibility
to cancer [16-21].
Because there is evidence that genetic factors and UV-
induced damage play a role in the development of pterygium
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discovered using the single nucleotide polymorphism (SNP)
method—and the polymorphisms of DNA repair genes have
an effect on host capacity of removing DNA damage, it is
logical to assume the correlation between pterygium and the
genetic  polymorphisms  of  DNA  repair  enzymes  XRCC1,
XPA, and XPD.
In this study, we selected polymorphisms in the 3 genes
based  upon  conservation  of  the  gene  sequence  through
evolution, frequency, and those occurring in exons resulting
in amino acid changes of potential functional significance
[24-26].  There  were  four  polymorphism  sites  studied  in
XRCC1: codon 107, 194, 280, and 399. Among them, most of
the published codon 194 polymorphism—an arginine (Arg)
to  Tryptophan  (Trp)  change  (C→T,  Arg194Trp)—studies
reported a reduced risk of cancer associated with the T allele
[25].  Codon  399  polymorphism—an  arginine  (Arg)  to
glutamine  (Gln)  change  (G→A,  Arg399Gln)—was  never
reported to be associated with cancer formation and deficient
DNA repair [19,25,27,28]. Only relatively small studies have
assessed that the less common codon 280 polymorphism and
its association with cancer was controversial [25]. There are
no reports about the codon 107 polymorphism and the risk of
tumors.  There  were  two  polymorphism  sites  identified  in
XPA:  A23G  and  codon  228  (G709A,  Arg228Gln)  [29].
Several  polymorphisms  were  reported  in  XPD,  but  XPD
codon 751 polymorphism (A→C, Lys751Gln) was reported
to affect the proficiency of DNA repair [18,20].
In the present study, we conducted a case control study
to  evaluate  the  associations  of  pterygium  formation  and
XRCC1 codon 107, 194, 280, and 399; XPA A23G; XPA
codon 228; and XPD codon 751 polymorphisms.
METHODS
Patients: A total of 127 pterygium patients (70 males and 57
females)  at  the  Department  of  Ophthalmology,  National
Cheng-  Kung  University  Hospital  (Tainan,  Taiwan)  from
January 2003 to June 2003 were enrolled in the study, with
ages ranging from 35 to 90 years (mean: 64.6 years). Patients
included in this study were apex of pterygium invading the
cornea for more than 1 mm. One hundred and three volunteers
aged 50 years or more without pterygium were enrolled as the
control group. There were 64 males and 39 females in the
control group (age range of 50 to 83 years with an average age
of 64.2). This study was performed with approval from the
Human Study Committee of the China Medical University
Hospital  and  National  Cheng  Kung  University  Hospital.
Informed  consent  was  obtained  from  all  individuals  who
participated in this study.
Genomic DNA was prepared from peripheral blood by
use of a DNA Extractor WB kit (Wako, Japan). Polymerase
chain reactions (PCRs) were performed in a total volume of
25 µl, containing genomic DNA; 2–6 pmol of each primer; 1×
Taq polymerase buffer (1.5 mM MgCl2); and 0.25 units of
AmpliTaq DNA polymerase (Perkin Elmer, Foster City, CA).
XRCC1 codon 107, 194, 280, and 399 polymorphisms: The
PCR conditions for XRCC1 codon 107, 194, 280, and 399
polymorphisms were designed by us using EntrezGene. The
PCR condition was initiated by a 5 min denaturation step at
95 °C, followed by 35 cycles at 95 °C for 30 s, 58 °C, 58 °C,
63 °C, 60 °C for XRCC1 codon 107, 194, 280, and 399,
respectively, for 30 s, 72 °C for 30 s, and a final step at 72 °C
for 7 min. The PCR products were subjected to restriction
digestion overnight at 37 °C by RsaI, HpaII, NciI, and MspI
for XRCC1 codon 107, 194, 280, and 399, respectively. The
primers and probes for XRCC1 polymorphisms are listed in
Table 1.
XPA  A23G,  XPA  codon  228,  and  XPD  codon  751
polymorphisms: The method of determining the XPA A23G,
XPA codon 228, and XPD codon 751 genotypes was the same
as the previous study [17,20]. The PCR primers for the XPA
TABLE 1. THE PRIMERS AND PROBES FOR XRCC1, XPA, AND XPD POLYMORPHISMS.
Polymorphism Primer sequence
XRCC1 codon 107 F: 5'-TTGACCCCCAGTGGTGCT-3’
R: 5'-AGTCTGCTGGCTCTGGGCTGG-3'
XRCC1 codon 194 F: 5'-CAGACAAAGATGAGGCAGAGG-3'
R: 5'-TCAGACCCAGGAATCTGAGC-3'
XRCC1 280 F: 5'-CATCTCTCCCTTGGTCTCCA-3’
R: 5'-CAGGATAAGGAGCAGGGTTG-3'
XRCC1 399 F: 5'-GGACTGTCACCGCATGCGTCGG-3'
R: 5'-GGCTGGGACCACCTGTGTT-3'
XPA A23G F: 5’-TTAACTGCGCAGGCGCTCTCACTC-3’
R: 5’-AAAGCCCCGTCGGCCGCCGCCAT-3’
XPA codon 228 F: 5’-TTTTCAGAATTGCGTC-3’
R: 5’-TTCATATGTCAGTTCATG-3’
XPD codon 751 F: 5’-GCCCGCTCTGGATTATACG-3’
R: 5’-CTATCATCTCCTGGCCCCC-3’
In the table, "F" indicates forward primer and "R" indicates reverse primer.
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699A23G, codon 228 and XPD codon 751 polymorphism are list
in  Table 1.  Briefly, PCR  reactions  were performed  in a 20-
μl reaction volume containing 200 ng of genomic DNA, 10
pmol  of  each  primer,  0.2  mm    each  deoxynucleotide
triphosphate, 1× PCR buffer (75 mm  Tris-HCl [pH 9.0], 15
mm ammonium sulfate, and 0.1 μg/μl BSA), 2.5 mm MgCl2,
and 1 unit of Taq polymerase (Takara Shuzo Co., Otsu, Shiga,
Japan).  The  mixture  were  amplified  with  a  Perkin-Elmer
GeneAmp PCR System 9600 (Perkin-Elmer, Foster, CA). The
PCR profile consisted of an initial melting step of 94 °C for 5
min, followed by 36 cycles of denaturation at 94 °C for 20 s;
primer annealing, 20 s at 58 °C for A23G and 20 s at 48 °C
for codon 228; and primer extension, 20 s at 72 °C for A23G
and 30 s at 72 °C for codon 228. The cycles were followed by
a final elongation step at 72 °C for 5 min for A23G and 10
min for codon 228. The PCR products were checked on a 2%
agarose gel, photographed using Polaroid film, and were then
subjected to RFLP analysis.
The PCR products from the same individual were mixed
together and 10 µl of this solution was loaded into 3% agarose
gel containing ethidium bromide for electrophoresis.
Statistical analysis for the distributions of the XRCC1
codon 107, 194, 280, 399, XPA A23G, XPA codon 228, and
XPD codon 751 polymorphisms in the control group and
pterygium group were compared using the χ2 test. The risk of
pterygium was estimated using the odds ratio (OR) and a 95%
confidence interval (CI).
RESULTS
There were no significant differences between the groups in
age or sex. The frequencies of the genotypes and alleles of
XRCC1 codon 107, 194, 280, and 399 polymorphisms in the
pterygium group and control group are shown in Table 2 and
Table  3.  There  were  significant  differences  between  the
groups  in  codon  194  and  399  polymorphisms  and  no
differences in codon 107 and 280.
In  the  XRCC1  codon  194  polymorphism  (C→T,
Arg194Trp), the odds ratio of C/T polymorphism was 0.979
and T/T polymorphism was 0.292 compared to the C/C wild-
type genotype. Hence, individuals who carried at least 1 T
(Trp) allele (C/T and T/T) had a decreased risk, or a protective
effect,  of  developing  pterygium  compared  to  those  who
carried  the  C/C  (Arg/Arg)  wild-type  genotype  (OR=0.58;
95%  CI:  0.34–0.98).  Those  who  carried  allele  T  had  a
decreased risk, or a protective effect, of developing pterygium
compared to those who carried allele C (OR=0.473; 95% CI:
0.325–0.689).
In  the  XRCC1  codon  399  polymorphism  (G→A,
Arg399Gln), the odds ratio of G/A polymorphism was 3.15
TABLE 2. GENOTYPES AND ALLELIC FREQUENCIES FOR XRCC1 CODON 399 POLYMORPHISM (G→A, ARG399GLN) IN THE PTERYGIUM AND CONTROL GROUP.
Polymorphism Pterygium total=127 (%) Control total=103 (%) OR (95% CI)
Genotype
GG 48 (37.8) 67 (65.0) 1
GA 70 (55.1) 31 (30.1) 3.152 (1.796–5.531)
AA 9 (7.1) 5 (4.9) 2.513 (0.792–7.969)
GA or AA 79 (62.2) 36 (35.0) 3.063 (1.783–5.262)
Allele
G 166 (65.4) 165 (80.1) 1
A 88 (34.6) 41 (19.9) 2.133 (1.390–3.275)
TABLE 3. DISTRIBUTION OF ALLELIC FREQUENCY OF XRCC1 CODON 107, 194, 280, 399, XPA A23G AND XPD CODON 751 POLYMORPHISMS.
Polymorphism Pterygium 127 Control 103 p OR
XRCC1 codon 107 (A→G)     0.82  
Allele A 203 (79.9%) 162 (78.6%)   1
Allele G 51 (20.1%) 44 (21.4%)   0.925 (0.589–1.452)
XRCC1 codon 194 (C→T)     0.0001  
Allele C 167 (65.8%) 98 (47.6%)   1
Allele T 87 (34.2%) 108 (52.4%)   0.473 (0.325–0.689)
XRCC1 codon 280 (G→A)     0.51  
Allele G 189 (74.4%) 159 (77.2%)   1
Allele A 65 (25.6%) 47 (22.8%)   1.163 (0.758–1.787)
XRCC1 codon 399 (G→A)     0.001  
Allele G 168 (66.1%) 165 (80.1%)   1
Allele A 86 (33.9%) 41 (19.9%)   2.060 (1.343–3.160)
XPA A23G (A→G)     0.54  
Allele A 122 (48%) 93 (45.1%)   1
Allele G 132 (52%) 113 (54.9%)   0.89 (0.616–1.287)
XPD codon 751 (A→C)     0.17  
Allele A 235 (92.5%) 197 (95.6%)   1
Allele C 19 (7.5%) 9 (4.4%)   1.77 (0.797–3.924)
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700and A/A polymorphism was 2.51 compared to the G/G wild-
type genotype. Hence, individuals who carried at least 1 A
(Gln) allele (G/A and A/A) had a threefold increased risk of
developing pterygium compared to those who carried the G/
G (Arg/Arg) wild-type genotype (OR=3.06; 95% CI: 1.78–
5.26). Those who carried allele A had a twofold increased risk
of developing pterygium compared to those who carried allele
G (OR=2.13; 95% CI: 1.39–3.28).
The frequency of the genotypes and alleles of XPA A23G
and XPD codon 751 polymorphisms in the pterygium group
and control group is shown in Table 2 and Table 3. There were
no significant differences between the groups. The XPA codon
228 (G709A, Arg228Gln) polymorphism was not detected in
the cases or controls; all patients were GG (Arg/Arg) wild-
type genotypes.
DISCUSSION
This  is  the  first  case-control  study  of  polymorphisms  in
XRCC1 codon 107, 194, 280, and 399; XPA A23G; XPA
codon 228; and XPD codon 751 in relation to pterygium
formation. In our study, we found that the XRCC1 codon 194
polymorphism  was  associated  with  a  decreased  risk  of
developing pterygium, and that the codon 399 polymorphism
was associated with susceptibility to pterygium. The XRCC1
codon  107  and  280,  XPA  A23G,  and  XPD  codon  751
polymorphisms  were  not  associated  with  pterygium
formation. The XPA codon 228 (G709A) polymorphism was
not detected in the cases and controls; we suggest that this is
due to ethnic differences, as in the report of Park et al. [17].
XRCC1, XPA, and XPD are all DNA repair genes. The
difference between XPA and XPD, and XRCC1 is that XPA and
XPD are NER, and XRCC1 is BER. The BER pathway repairs
small  base  adducts  that  are  produced  by  oxidation,
methylation, and radiation, whereas the NER pathway repairs
bulky  and  helix-distorting  adducts  induced  by  chemical
carcinogens and radiation [11-13]. The noxious effects of UV
irradiation on DNA are either directly by the UV phototoxic
effect or indirectly by oxidative stress [9-11]. Both the UV
phototoxic effect and oxidative stress mainly produce single
base changes and tandem mutations in DNA [11,30]. Single
base changes are normally reversed by the BER system and
tandem  mutations  are  repaired  by  the  NER  system  [11,
30-33]. Hence, among the five major DNA repair systems,
NER and BER are the main systems involved in repairing UV-
induced DNA damage [11].
Because pterygium is a UV-induced disease, we assume
that both BER and NER play a role in pterygium formation.
XRCC1  and  human  8-oxoguanine  DNA  glycosylase  1
(hOGG1) are BER system genes and XRCC1, in our series,
and hOGG1, in the report of Kau et al. [22] , are found to be
associated  with  pterygium  formation;  therefore,  the  BER
system indeed plays an important role in pterygium formation.
However, XPA and XPD— NER system genes—are not found
to be associated with pterygium in our series. We suggest that
the  different  result  may  be  due  to  the  following  three
possibilities: First, it is other polymorphisms in XPA and XPD
and not the XPA A23G, XPA codon 228, and XPD codon 751
polymorphisms  that  are  involved  in  pterygium  formation.
Second, it is other genes in NER, not XPA or XPD, that are
involved in pterygium formation. Third, it is BER and other
DNA repair systems, not NER, that play a role in pterygium
formation.
NER is a complex process involving more than 30 gene
products, and XPA and XPD are two important genes among
these  [11].  XPA  plays  a  central  role  in  NER  through  its
interaction with the replication protein A, transcription factor
TFIIH, and excision repair cross-complementing group 1-
XPF [11,14,15]. XPD encodes a helicase, which participates
in both NER and basal transcription as part of the transcription
factor TFIIH [33]. Polymorphisms of XPA A23G and XPD
codon 751 were reported to have a modulating effect on NER
capacity [16,18,20]. If the XPA A23G and XPD codon 751
polymorphisms, like in other tissues, are correlated with the
DNA repair capacity of NER in the conjunctiva and cornea,
the result of polymorphisms of XPA A23G and XPD codon
751  not  associated  being  with  pterygium  formation  may
suggest  that  the  NER  system  might  not  play  a  role  in
pterygium formation; however, more evidence is required to
support this theory.
Analysis of the gene mutation spectrum in pterygium is
a method of evaluating the role of BER and NER in pterygium.
We suggest that UV radiation can produce single base changes
and tandem mutations in the conjunctiva and cornea, as in
other tissues. When both NER and BER are normal in the
conjunctiva  and  cornea,  all  mutations  can  be  repaired.
However, when the NER system is intact, but the BER system
has reduced activity, only tandem mutations are repaired and
single base changes are not, and vice versa. In our previous
study, all p53 gene mutations in pterygium were single base
changes, not tandem mutations [4]. Hence, we suggest that the
function of the NER system is normal in pterygium, but that
of the BER system has reduced activity. If the NER system in
pterygium is the same as that of normal people, it is reasonable
that  XPA  and  XPD  polymorphisms  were  not  found  to  be
differently distributed between those with pterygium and the
normal  controls.  If  pterygium  is  associated  with  reduced
activity of the BER system, it is reasonable that the XRCC1
and  hOGG1  polymorphisms  were  found  to  be  differently
distributed  between  those  with  pterygium  and  the  normal
controls. This is because the polymorphisms of XRCC1 and
hOGG1 have a different DNA repair capacity [19,28], and
people  who  have  polymorphism  with  lower  DNA  repair
activity are prone to pterygium.
Among  XRCC1  polymorphisms,  codon  399
polymorphism  was  well  studied  and  was  found  to  be
associated with formation of several cancers [19,27,34,35],
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701but the exact biochemical effect of the polymorphism is not
fully characterized. XRCC1 plays a pivotal role in BER by
bringing together DNA polymerase-β, DNA ligase III, and
PARP at the site of DNA damage. The codon 399 variant lies
within the BRCT-1 domain of XRCC1. The BRCT-1 domain
is a region with extensive homology to BRCA1 and includes
a binding site for PARP [12,13,36]. Therefore, the amino acid
substitutions in codon 399 are proposed to change the function
of  the  protein,  and  the  399Gln  allele  of  XRCC1  has  an
important and potentially harmful phenotype and is reported
to be associated with cancer [19,27,28,34-37]. Our finding of
a  positive  association  between  the  XRCC1  codon  399Gln
allele  and  pterygium  is  consistent  with  the  published,
functional studies [28,37].
Sturgis et al. [34] reported an OR of 1.6 (95% CI, 1.0–
2.6) for the XRCC1 codon 399 Gln/Gln genotype in a case-
control study of head and neck cancer, and Divine et al. [35]
observed an odds ratio of 2.8 (95% CI, 1.2–7.9) for XRCC1
codon 399 Gln/Gln genotype in a case-control study of lung
cancer.  However,  there  was  study  that  reported  contrary
findings: Stern et al. [27] observed an inverse association
between XRCC1 codon 399 Gln/Gln genotype and bladder
cancer. In our series, individuals who carried at least 1 A (Gln)
allele had a threefold increased risk (OR=3.06; 95% CI: 1.78–
5.26) of developing pterygium compared to those who carried
the GG (Arg/Arg) wild-type genotype, which is consistent
with most epidemiological studies [19,28,34,35,37].
A second XRCC1 polymorphism (Arg194Trp) has also
been  well  studied,  and  most  of  the  published  codon  194
polymorphism  studies  reported  a  reduced  risk  of  cancer
associated with the Trp allele [25,27,34,38]. The reported odd
ratio  was  from  0.4  to  0.7  [25,27,34,38].  In  our  series,
individuals who carried at least 1 T (Trp) allele (C/T and T/
T)  also  had  a  decreased  risk  of  developing  pterygium
compared to those who carried the C/C (Arg/Arg) wild-type
genotype (OR=0.58; 95% CI: 0.34–0.98), which is consistent
with  most  of  the  published  studies  reporting  inverse
associations between the XRCC1 194Trp allele and cancer
risk at many sites [25].
XRCC1  codon  194  polymorphism  results  from  a
transition from a positively charged Arg to a hydrophobic Trp,
which may alter XRCC1 function; however, human studies of
XRCC1 Arg194Trp have reported no associations with the
indicators  of  DNA-repair  capacity,  such  as  DNA-adduct
levels, frequency of mutations in glycophorin A, or sensitivity
to ionizing radiation [28,39,40]. Hence, the mechanism of this
polymorphism’s  inverse  association  with  cancer  and
pterygium  is  still  unknown.  Because  the  functional
significance of the Arg194Trp region is not clear, more studies
are needed to define its role.
There were two limitations in our study. First, we didn’t
stratify the study population in terms of severity. There were
numerous classification systems in pterygium, e.g., atrophic,
intermediate,  and  fleshy  type  based  on  the  relative
translucency of the body. While pooling all of the patients’
data together provided a general overview of the risks of
genetic polymorphism, we suggest that the dichotomy of our
patients’  data  according  to  classification  systems  might
provide further insight into the pathogenesis of pterygium.
Further study is recommended. Second, we could not show
that the AA polymorphism of XRCC1 codon 399 created a
significant risk of developing pterygium (OR=2.513; 95% CI:
0.792–7.969). Because there are only nine pterygium patients
and five normal controls with AA polymorphism, we can’t
have  the  significantly  different  result  in  analysis  of  this
genotype due to the small number of the sample. Hence, we
could not show that AA polymorphism created a significant
risk of developing pterygium, and we also could not show that
the presence of GA polymorphism partially negates the risks
of developing pterygium when compared with AA. However,
we  found  that  the  presence  of  allele  A  meant  a  twofold
increased risk of developing pterygium compared to allele G,
and individuals who carried at least 1 A (Gln) allele (GA and
AA) had a threefold increased risk of developing pterygium
compared to those who carried the GG (Arg/Arg) wild-type
genotype. These results support the theory that the XRCC1
codon 399 polymorphism is associated with pterygium.
In conclusion, our study demonstrated for the first time
that  the  XRCC1  codon  194  polymorphism  is  inversely
associated  with  pterygium,  and  that  the  codon  399
polymorphism  is  associated  with  the  risk  of  pterygium.
Polymorphisms of XPA A23G and XPD codon 751 are not
associated with pterygium formation. Further studies on the
polymorphisms of other genes in NER, BER, or other DNA
repair systems are necessary for the detection of a genetic
predisposition  to  pterygium  formation  and  for  the
investigation of the roles of NER, BER, or other DNA repair
genes in pterygium formation.
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